---
document_datetime: 2025-12-02 06:34:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/daklinza.html
document_name: daklinza.html
version: success
processing_time: 0.1195427
conversion_datetime: 2025-12-27 21:49:38.364154
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Daklinza

[RSS](/en/individual-human-medicine.xml/65416)

##### Expired

This medicine's authorisation has expired

daclatasvir Medicine Human Expired

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Daklinza](#news-on)
- [Related content](#related-content-434)
- [More information on Daklinza](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Daklinza (daclatasvir) expired on 26 August 2019 following the decision of the marketing authorisation holder, Bristol-Myers Squibb Pharma EEIG, not to apply for a renewal of the marketing authorisation for commercial reasons.

Daklinza was granted marketing authorisation in the European Union (EU) on 22 August 2014 for the treatment of chronic hepatitis C virus (HCV) infection in adults. The marketing authorisation was valid for 5 years.

The European Public Assessment Report (EPAR) for Daklinza is updated to indicate that the marketing authorisation is no longer valid.

Daklinza : EPAR - Summary for the public

Reference Number: EMA/525602/2014

English (EN) (545.44 KB - PDF)

**First published:** 15/09/2014

[View](/en/documents/overview/daklinza-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-74)

български (BG) (628.18 KB - PDF)

**First published:**

15/09/2014

[View](/bg/documents/overview/daklinza-epar-summary-public_bg.pdf)

español (ES) (543.49 KB - PDF)

**First published:**

15/09/2014

[View](/es/documents/overview/daklinza-epar-summary-public_es.pdf)

čeština (CS) (609.58 KB - PDF)

**First published:**

15/09/2014

[View](/cs/documents/overview/daklinza-epar-summary-public_cs.pdf)

dansk (DA) (542.71 KB - PDF)

**First published:**

15/09/2014

[View](/da/documents/overview/daklinza-epar-summary-public_da.pdf)

Deutsch (DE) (546.46 KB - PDF)

**First published:**

15/09/2014

[View](/de/documents/overview/daklinza-epar-summary-public_de.pdf)

eesti keel (ET) (540.28 KB - PDF)

**First published:**

15/09/2014

[View](/et/documents/overview/daklinza-epar-summary-public_et.pdf)

ελληνικά (EL) (631.92 KB - PDF)

**First published:**

15/09/2014

[View](/el/documents/overview/daklinza-epar-summary-public_el.pdf)

français (FR) (544.71 KB - PDF)

**First published:**

15/09/2014

[View](/fr/documents/overview/daklinza-epar-summary-public_fr.pdf)

hrvatski (HR) (564.65 KB - PDF)

**First published:**

15/09/2014

[View](/hr/documents/overview/daklinza-epar-summary-public_hr.pdf)

italiano (IT) (542.93 KB - PDF)

**First published:**

15/09/2014

[View](/it/documents/overview/daklinza-epar-summary-public_it.pdf)

latviešu valoda (LV) (607.76 KB - PDF)

**First published:**

15/09/2014

[View](/lv/documents/overview/daklinza-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (568.71 KB - PDF)

**First published:**

15/09/2014

[View](/lt/documents/overview/daklinza-epar-summary-public_lt.pdf)

magyar (HU) (602.84 KB - PDF)

**First published:**

15/09/2014

[View](/hu/documents/overview/daklinza-epar-summary-public_hu.pdf)

Malti (MT) (647.47 KB - PDF)

**First published:**

15/09/2014

[View](/mt/documents/overview/daklinza-epar-summary-public_mt.pdf)

Nederlands (NL) (543.11 KB - PDF)

**First published:**

15/09/2014

[View](/nl/documents/overview/daklinza-epar-summary-public_nl.pdf)

polski (PL) (608.14 KB - PDF)

**First published:**

15/09/2014

[View](/pl/documents/overview/daklinza-epar-summary-public_pl.pdf)

português (PT) (543.83 KB - PDF)

**First published:**

15/09/2014

[View](/pt/documents/overview/daklinza-epar-summary-public_pt.pdf)

română (RO) (568.41 KB - PDF)

**First published:**

15/09/2014

[View](/ro/documents/overview/daklinza-epar-summary-public_ro.pdf)

slovenčina (SK) (608.8 KB - PDF)

**First published:**

15/09/2014

[View](/sk/documents/overview/daklinza-epar-summary-public_sk.pdf)

slovenščina (SL) (601.12 KB - PDF)

**First published:**

15/09/2014

[View](/sl/documents/overview/daklinza-epar-summary-public_sl.pdf)

Suomi (FI) (542.26 KB - PDF)

**First published:**

15/09/2014

[View](/fi/documents/overview/daklinza-epar-summary-public_fi.pdf)

svenska (SV) (542.83 KB - PDF)

**First published:**

15/09/2014

[View](/sv/documents/overview/daklinza-epar-summary-public_sv.pdf)

Daklinza : EPAR - Risk-management-plan summary

English (EN) (751.3 KB - PDF)

**First published:** 15/09/2014

**Last updated:** 28/05/2019

[View](/en/documents/rmp-summary/daklinza-epar-risk-management-plan-summary_en.pdf)

## Product information

Daklinza : EPAR - Product Information

English (EN) (1.48 MB - PDF)

**First published:** 15/09/2014

**Last updated:** 22/08/2019

[View](/en/documents/product-information/daklinza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-283)

български (BG) (2.6 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/bg/documents/product-information/daklinza-epar-product-information_bg.pdf)

español (ES) (1.52 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/es/documents/product-information/daklinza-epar-product-information_es.pdf)

čeština (CS) (2.17 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/cs/documents/product-information/daklinza-epar-product-information_cs.pdf)

dansk (DA) (1.5 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/da/documents/product-information/daklinza-epar-product-information_da.pdf)

Deutsch (DE) (1.56 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/de/documents/product-information/daklinza-epar-product-information_de.pdf)

eesti keel (ET) (1.5 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/et/documents/product-information/daklinza-epar-product-information_et.pdf)

ελληνικά (EL) (2.72 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/el/documents/product-information/daklinza-epar-product-information_el.pdf)

français (FR) (1.55 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/fr/documents/product-information/daklinza-epar-product-information_fr.pdf)

hrvatski (HR) (1.51 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/hr/documents/product-information/daklinza-epar-product-information_hr.pdf)

íslenska (IS) (1.5 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/is/documents/product-information/daklinza-epar-product-information_is.pdf)

italiano (IT) (1.52 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/it/documents/product-information/daklinza-epar-product-information_it.pdf)

latviešu valoda (LV) (2.2 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/lv/documents/product-information/daklinza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.51 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/lt/documents/product-information/daklinza-epar-product-information_lt.pdf)

magyar (HU) (2.2 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/hu/documents/product-information/daklinza-epar-product-information_hu.pdf)

Malti (MT) (2.2 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/mt/documents/product-information/daklinza-epar-product-information_mt.pdf)

Nederlands (NL) (1.53 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/nl/documents/product-information/daklinza-epar-product-information_nl.pdf)

norsk (NO) (1.49 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/no/documents/product-information/daklinza-epar-product-information_no.pdf)

polski (PL) (2.23 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/pl/documents/product-information/daklinza-epar-product-information_pl.pdf)

português (PT) (1.51 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/pt/documents/product-information/daklinza-epar-product-information_pt.pdf)

română (RO) (1.54 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/ro/documents/product-information/daklinza-epar-product-information_ro.pdf)

slovenčina (SK) (2.18 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/sk/documents/product-information/daklinza-epar-product-information_sk.pdf)

slovenščina (SL) (2.15 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/sl/documents/product-information/daklinza-epar-product-information_sl.pdf)

Suomi (FI) (1.51 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/fi/documents/product-information/daklinza-epar-product-information_fi.pdf)

svenska (SV) (1.5 MB - PDF)

**First published:**

15/09/2014

**Last updated:**

22/08/2019

[View](/sv/documents/product-information/daklinza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0034 24/07/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Daklinza : EPAR - All Authorised presentations

English (EN) (499.41 KB - PDF)

**First published:** 15/09/2014

[View](/en/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-627)

български (BG) (538.09 KB - PDF)

**First published:**

15/09/2014

[View](/bg/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_bg.pdf)

español (ES) (480.15 KB - PDF)

**First published:**

15/09/2014

[View](/es/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (519.28 KB - PDF)

**First published:**

15/09/2014

[View](/cs/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (479.99 KB - PDF)

**First published:**

15/09/2014

[View](/da/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (500.02 KB - PDF)

**First published:**

15/09/2014

[View](/de/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (503.01 KB - PDF)

**First published:**

15/09/2014

[View](/et/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (538.57 KB - PDF)

**First published:**

15/09/2014

[View](/el/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_el.pdf)

français (FR) (502.55 KB - PDF)

**First published:**

15/09/2014

[View](/fr/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (522.16 KB - PDF)

**First published:**

15/09/2014

[View](/hr/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (480.79 KB - PDF)

**First published:**

15/09/2014

[View](/is/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_is.pdf)

italiano (IT) (479.78 KB - PDF)

**First published:**

15/09/2014

[View](/it/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (531.41 KB - PDF)

**First published:**

15/09/2014

[View](/lv/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (517.54 KB - PDF)

**First published:**

15/09/2014

[View](/lt/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (530.57 KB - PDF)

**First published:**

15/09/2014

[View](/hu/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (506.8 KB - PDF)

**First published:**

15/09/2014

[View](/mt/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (479.41 KB - PDF)

**First published:**

15/09/2014

[View](/nl/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (480.09 KB - PDF)

**First published:**

15/09/2014

[View](/no/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_no.pdf)

polski (PL) (522.36 KB - PDF)

**First published:**

15/09/2014

[View](/pl/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_pl.pdf)

português (PT) (484.19 KB - PDF)

**First published:**

15/09/2014

[View](/pt/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_pt.pdf)

română (RO) (494 KB - PDF)

**First published:**

15/09/2014

[View](/ro/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (522.76 KB - PDF)

**First published:**

15/09/2014

[View](/sk/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (521.74 KB - PDF)

**First published:**

15/09/2014

[View](/sl/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (479.66 KB - PDF)

**First published:**

15/09/2014

[View](/fi/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (502.37 KB - PDF)

**First published:**

15/09/2014

[View](/sv/documents/all-authorised-presentations/daklinza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Daklinza Active substance daclatasvir dihydrochloride International non-proprietary name (INN) or common name daclatasvir Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AP07

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1).

For HCV genotype specific activity, see sections 4.4 and 5.1.

## Authorisation details

EMA product number EMEA/H/C/003768

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 26/06/2014 Marketing authorisation issued 22/08/2014 Expiry of marketing authorisation 26/08/2019 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Daklinza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (722.28 KB - PDF)

**First published:** 10/11/2014

**Last updated:** 22/08/2019

[View](/en/documents/procedural-steps-after/daklinza-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Daklinza : EPAR - Scientific Conclusion

English (EN) (538.81 KB - PDF)

**First published:** 10/03/2017

[View](/en/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_en.pdf)

[Other languages (22)](#file-language-dropdown-356)

български (BG) (687.45 KB - PDF)

**First published:**

10/03/2017

[View](/bg/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_bg.pdf)

español (ES) (530.79 KB - PDF)

**First published:**

10/03/2017

[View](/es/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_es.pdf)

čeština (CS) (637.34 KB - PDF)

**First published:**

10/03/2017

[View](/cs/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_cs.pdf)

dansk (DA) (532.07 KB - PDF)

**First published:**

10/03/2017

[View](/da/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (542.71 KB - PDF)

**First published:**

10/03/2017

[View](/de/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (528.43 KB - PDF)

**First published:**

10/03/2017

[View](/et/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (698.83 KB - PDF)

**First published:**

10/03/2017

[View](/el/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_el.pdf)

français (FR) (530.89 KB - PDF)

**First published:**

10/03/2017

[View](/fr/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (572.64 KB - PDF)

**First published:**

10/03/2017

[View](/hr/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_hr.pdf)

italiano (IT) (538.07 KB - PDF)

**First published:**

10/03/2017

[View](/it/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (664.34 KB - PDF)

**First published:**

10/03/2017

[View](/lv/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (575.28 KB - PDF)

**First published:**

10/03/2017

[View](/lt/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_lt.pdf)

magyar (HU) (616.83 KB - PDF)

**First published:**

10/03/2017

[View](/hu/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_hu.pdf)

Malti (MT) (649.44 KB - PDF)

**First published:**

10/03/2017

[View](/mt/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (537.08 KB - PDF)

**First published:**

10/03/2017

[View](/nl/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_nl.pdf)

polski (PL) (648.49 KB - PDF)

**First published:**

10/03/2017

[View](/pl/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_pl.pdf)

português (PT) (538.2 KB - PDF)

**First published:**

10/03/2017

[View](/pt/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_pt.pdf)

română (RO) (576.84 KB - PDF)

**First published:**

10/03/2017

[View](/ro/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (631.53 KB - PDF)

**First published:**

10/03/2017

[View](/sk/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (650.63 KB - PDF)

**First published:**

10/03/2017

[View](/sl/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (528.94 KB - PDF)

**First published:**

10/03/2017

[View](/fi/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_fi.pdf)

svenska (SV) (536.57 KB - PDF)

**First published:**

10/03/2017

[View](/sv/documents/scientific-conclusion/daklinza-epar-scientific-conclusion_sv.pdf)

Daklinza-H-C-3768-A-20-0016 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/103226/2017

English (EN) (955.08 KB - PDF)

**First published:** 10/03/2017

[View](/en/documents/variation-report/daklinza-h-c-3768-20-0016-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Daklinza : EPAR - Public assessment report

Adopted

Reference Number: EMA/419836/2014

English (EN) (5.38 MB - PDF)

**First published:** 15/09/2014

**Last updated:** 15/09/2014

[View](/en/documents/assessment-report/daklinza-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Daklinza

Adopted

Reference Number: EMA/CHMP/372924/2014

English (EN) (522.48 KB - PDF)

**First published:** 27/06/2014

**Last updated:** 27/06/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-daklinza_en.pdf)

#### News on Daklinza

[Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B](/en/news/direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b) 16/12/2016

[PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C](/en/news/prac-warns-risk-hepatitis-b-re-activation-direct-acting-antivirals-hepatitis-c) 02/12/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

[EMA recommends avoidance of certain hepatitis C medicines and amiodarone together](/en/news/ema-recommends-avoidance-certain-hepatitis-c-medicines-amiodarone-together) 24/04/2015

[World Hepatitis Day - European Medicines Agency uses regulatory tools to facilitate patient access to innovative medicines](/en/news/world-hepatitis-day-european-medicines-agency-uses-regulatory-tools-facilitate-patient-access-innovative-medicines) 25/07/2014

[European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014](/en/news/european-medicines-agency-recommends-39-medicines-human-use-marketing-authorisation-first-half-2014) 10/07/2014

[European Medicines Agency recommends approval of Daklinza in chronic hepatitis C](/en/news/european-medicines-agency-recommends-approval-daklinza-chronic-hepatitis-c) 27/06/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 June 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-june-2014) 27/06/2014

#### Related content

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC003768X0013) (extension X/0013)

#### More information on Daklinza

- [EMEA-001191-PIP01-11-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001191-pip01-11-m03)
- [Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free) - referral](/en/medicines/human/referrals/direct-acting-antivirals-indicated-treatment-hepatitis-c-interferon-free)
- [A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (De Novo DAA PASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/44706)

**This page was last updated on** 30/08/2019

## Share this page

[Back to top](#main-content)